AbbVie Inc (ABBV)vsOmniAb Inc. (OABI)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
OABI
OmniAb Inc.
$2.48
-6.77%
HEALTHCARE · Cap: $347.93M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 216974% more annual revenue ($62.82B vs $28.94M). ABBV leads profitability with a 5.8% profit margin vs -187.6%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
OABI
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for OABI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
Revenue surging 247.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -20.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : OABI
The strongest argument for OABI centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 247.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : OABI
The primary concerns for OABI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while OABI is a hypergrowth play — different risk/reward profiles.
OABI carries more volatility with a beta of 1.15 — expect wider price swings.
OABI is growing revenue faster at 247.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 34/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
OmniAb Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
OmniAb Inc. is an innovative biotechnology company specializing in the development of fully human therapeutic antibodies via its proprietary OmniAb platform. This advanced technology enables the swift discovery and refinement of highly effective therapies aimed at addressing a wide spectrum of diseases. By leveraging strategic partnerships and collaborations, OmniAb aims to accelerate drug development processes and enhance access to groundbreaking treatments. With a seasoned leadership team and a robust pipeline of candidates, the company is strategically positioned to capitalize on the growing opportunities within the biopharmaceutical industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?